Page 578 - Cardiac Nursing

9 A
8:2
8:2
9 A
P
M
M
0
9/2
9/0
9/0
9/2
0
009
009
54
54
54
Apt
ara
ara
Apt
e 5
a
P
P
a
e 5
g
g
0
23_
0-c
0-c
p53
p53
23_
L L LWB
LWB
LWBK340-c23_23_p537-554.qxd 09/09/2009 08:29 AM Page 554 Aptara
K34
K34
K34
7-5
54.
0
7-5
qxd
qxd
54.
54.
554 PA R T I V / Pathophysiology and Management of Heart Disease
Academy of Neurology affirms the value of this guideline. Circulation, coronary artery disease: A randomized controlled trial. Journal of the Amer-
113(10), e409–e449. ican College of Cardiology, 48(12), 2440–2447.
84. Dowson, A., Mullen, M. J., Peatfield, R., et al. (2008). Migraine Inter- 86. Serruys, P. W., & Ruygrok, P. (2006). A randomized comparison of an
vention With STARFlex Technology (MIST) trial: A prospective, multi- everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent:
center, double-blind, sham-controlled trial to evaluate the effectiveness of The SPIRIT II trial. Eurointervention, 2, 286–294.
patent foramen ovale closure with STARFlex septal repair implant to re- 87. Ormiston, J. A., Serruys, P. W., Regar, E., et al. (2008). A bioabsorbable
solve refractory migraine headache. Circulation, 117(11), 1397–1404. everolimus-eluting coronary stent system for patients with single de-novo
7
7
85. Kandzari, D. E., Leon, M. B., Popma, J. J., et al. (2006). Comparison of coronary artery lesions (ABSORB): A prospective open-label trial. Lancet,
zotarolimus-eluting and sirolimus-eluting stents in patients with native 371(9616), 899–907.